Literature DB >> 6177233

Interferon in cancer: Faith, hope and reality.

H Strander, S Einhorn.   

Abstract

Patients that have received interferon therapy for tumor diseases to date do not total more than a few hundred. Remissions have been reported in some patients with various types of malignant tumors. This is interesting, as interferon therapy represents a new principle in the treatment of tumor diseases. However, prolonged and complete remissions have been rare, and we are not yet in a position to say whether interferon therapy is superior to other treatment methods in current use for any type of malignant tumor. If this proves to be the case for some such diseases, we would still be faced with the tasks of identifying patients that may benefit from the interferon treatment, and of establishing the best procedure for its application. Research toward these ends would be greatly facilitated by the development of methods for producing interferon.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6177233     DOI: 10.1097/00000421-198206000-00011

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  4 in total

1.  Influence of human interferon-alpha therapy on cytotoxic functions of blood lymphocytes. Studies on lectin-dependent cellular cytotoxicity, antibody-dependent cellular cytotoxicity, and natural killer cell activity.

Authors:  S Einhorn; H Blomgren; H Strander; J Wasserman
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

2.  Effect of rat and beta-human interferons on hyperacute experimental allergic encephalomyelitis in rats.

Authors:  F Hertz; R Deghenghi
Journal:  Agents Actions       Date:  1985-07

3.  Decrease in the phagocytic activity of peripheral monocytes in patients treated with human interferon-alpha.

Authors:  S Einhorn; C Jarstrand
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

4.  Interferon induces proliferation and differentiation in primary chronic lymphocytic leukaemia cells.

Authors:  K H Robert; S Einhorn; G Juliusson; L Ostlund; P Biberfeld
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.